Two molecules that promise a new type of therapy for cancer patients are scheduled to reach the clinical trial phase this year, Servier Hungaria, the Hungarian unit of the French pharmaceutical company, told a press conference on Thursday. Based on Hungarian research, one of the molecules would be used to treat aggressive blood cancer and the other colon-rectal cancer, Servier Hungaria’s cheif executive Jan-Frederic Kesselhut told a press conference held in Servier’s basic research institute in Óbuda.
Economy ministry state secretary Péter Cseresnyés hailed Servier’s work in uniting research and development and the country’s health economy. The company’s mixture of non-profit and for-profit positively impacts the health of Hungarians, supports scientific development and serves as a model for Hungarian small and medium-sized enterprises and start-ups, he said. Attila Beneda, interim state secretary for health care, noted that Servier is a government strategic partner. Servier has brought its R+D and clinical trials to Hungary, making a significant contribution both to the economy and to the health profession, he added.
EmoticonEmoticon